Literature DB >> 12853755

Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.

Lynn Morris1, Candice Pillay, Claudia Chezzi, Pumla Lupondwana, Matshediso Ntsala, Leon Levin, Francois Venter, Neil Martinson, Glenda Gray, James McIntyre.   

Abstract

Nevirapine used in single doses to prevent mother-to-child transmission has been shown to be associated with the development of transient resistant mutations. Here we describe the presence of V106M in seven out of 141 South African women (5%) 6 weeks after receiving nevirapine. V106M is a novel resistance mutation found in subtype C viruses exposed to efavirenz. This mutation is thus also induced at a low frequency in subtype C viruses exposed to single dose nevirapine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853755     DOI: 10.1097/00002030-200307250-00017

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.

Authors:  Louise Kuhn; Moses Sinkala; M P H Chipepo Kankasa; Prisca Kasonde; Donald M Thea; Grace M Aldrovandi
Journal:  J Acquir Immune Defic Syndr       Date:  2006-06       Impact factor: 3.731

Review 2.  Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.

Authors:  Carole L Wallis; Catherine Godfrey; Joseph E Fitzgibbon; John W Mellors
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

3.  Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.

Authors:  Heiko Karcher; Andrea Kunz; Gabriele Poggensee; Paulina Mbezi; Kizito Mugenyi; Gundel Harms
Journal:  MedGenMed       Date:  2006-04-12

4.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.

Authors:  Mohammad M Hossain; Michael A Parniak
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Daniela Moisi; Mervi Detorio; Raymond Cesaire; Takashi Kurimura; Haruyo Mori; Max Essex; Shlomo Maayan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.

Authors:  Ingrid A Beck; Claudia Crowell; Robin Kittoe; Helba Bredell; Molefe Machaba; Carolyn Willamson; Wouter Janssens; Sabelle Jallow; Guido van der Groen; Yiming Shao; Mini Jacob; N M Samuel; Ivette Lorenzana de Rivera; Nicole Ngo-Giang-Huong; Sharon Cassol; George Alemnji; Lisa M Frenkel
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

8.  Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.

Authors:  Zehava Grossman; Ellen E Paxinos; Diana Averbuch; Shlomo Maayan; Neil T Parkin; Dan Engelhard; Margalit Lorber; Valery Istomin; Yael Shaked; Ella Mendelson; Daniela Ram; Chris J Petropoulos; Jonathan M Schapiro
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

Authors:  Gerben van 't Klooster; Eva Hoeben; Herman Borghys; Adriana Looszova; Marie-Paule Bouche; Frans van Velsen; Lieven Baert
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

10.  Outcome of Different Nevirapine Administration Strategies in Preventin g Mother-to-Child Transmission (PMTCT) Programs in Tanzania and Uganda.

Authors:  Heiko Karcher; Andrea Kunz; Gabriele Poggensee; Paulina Mbezi; Kizito Mugenyi; Gundel Harms
Journal:  J Int AIDS Soc       Date:  2006-04-12       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.